← BackInspire Medical Systems, Inc. · Surgical & Medical Instruments & ApparatusINSP
Low riskNext report: In 5 days (est.)
The short versionA profitable company with shrinking sales.
Going well
- Profitable, keeps 16% of sales as profit
- Sales up 14% last year
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 9.4% to their holdings in the quarter ending June 2026 (161 bought, 164 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$70.99-0.1% that day
- Company value
- $2.1B
- Share price times all shares
- Price vs profit (P/E)
- 15.6x
- You pay about $16 for each $1 of yearly profit
- Price vs sales
- 2.3x
- Company value is 2.3 times a year of sales
- Cash vs value
- 6%
- Cash as a share of company value
From INSP's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$200.6M-7.6% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $898.7M, up 4.3% from the 12 months before. Over 5 years, sales grew about 51% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.19.8%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.15.9%
- MissProfitable every yearSteady profits, not one good year.2 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$78.5M
- MissShare count not growingNot diluting owners. Falling means buybacks.+6.0% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.85.4%
- Revenue
- $912.0M
- +13.6% vs prior year
- 5-year growth
- +51.2%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 6.08x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $200.6M
- -7.6% YoY
- EPS
- $0.01
- vs -$0.12
- Op. margin
- -0.3%
- +1.2 pts
- Gross margin
- 85.5%
- +1.5 pts
- Free cash flow
- $14.1M
- Share count
- -1.9%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.4
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
■Steady+9.4%Institutions added 9.4% to their holdings. 161 bought, 164 sold. 3 quarters of net buying in a row.
Shares held by institutions38.1M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-0.5%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
29MNext reportIn 5 days (est.)Estimated from the same quarter last year
- Results filedAug 3
- Results filedMay 4
- Results filedFeb 11
- Results filedJan 12
- Results filedNov 3, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.